Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06555263
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-12
Brief Title:
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Open-label Study Evaluating STRO-002 an Anti-folate Receptor Alpha FOLR1 Antibody-Drug Conjugate in Subjects With Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1
Detailed Description:
This is a multicenter open-label study The study is designed to assess the preliminary efficacy and safety of luveltamab tazevibulin an anti-FOLR1 antibody drug conjugate ADC in previously treated subjects with advanced or metastatic NSCLC that expresses FOLR1
Subjects will receive luveltamab tazevibulin administered intravenously every 3 weeks until disease progression intolerable toxicity elective withdrawal from the study or study termination
Subjects will receive luveltamab tazevibulin administered intravenously every 3 weeks until disease progression intolerable toxicity elective withdrawal from the study or study termination
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None